Table 4.
Percentage of Rotarix Vaccine Effect Explained by Rotavirus-Specific Immunoglobulin A on Rotavirus Diarrhea, Weeks 18–52
| Logistic Model | Variable | OR (95% CI) | P Value | % Vaccine Effect Explained by: |
|---|---|---|---|---|
| Vaccine arm + | Vaccine | 2.72 (1.79–4.14) | <.001 | Seropositivity: 7.8% |
| Seropositivity | Seropositivity | 2.24 (1.31–3.81) | .003 | |
| Vaccine arm + | Vaccine | 2.57 (1.69–3.19) | <.001 | RV-IgA (U/mL): 13.2% |
| Ln(RV-IgA) | Ln(RV-IgA) | 0.70 (.56–.87) | .001 |
Covariates included in each model: week 18 serum zinc concentration, exclusive breastfeeding at week 18, and treated water.
Abbreviations: CI, confidence interval; OR, odds ratio; RV-IgA, rotavirus-specific plasma IgA.